Dynavax Technologies | DVAX - Gross Profit On Sales

Stock Price
15.50
Daily Change
0.01 0.06%
Monthly
0.58%
Yearly
17.87%
Q1 Forecast
15.01

Dynavax Technologies reported $78.57M in Gross Profit on Sales for its fiscal quarter ending in June of 2025.





Gross Profit On Sales Change Date
AbbVie USD 10.47B 605M Sep/2025
Adma Biologics USD 75.63M 8.4M Sep/2025
Amgen USD 6.48B 307M Sep/2025
AstraZeneca USD 12.39B 406M Sep/2025
Biogen USD 1.65B 34.6M Dec/2025
BioMarin Pharmaceutical USD 631.2M 39.27M Sep/2025
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Dynavax Technologies USD 78.57M 24.17M Jun/2025
Gilead Sciences USD 5.58B 453M Jun/2025
Glaxosmithkline GBP 8.75B 2.92B Sep/2025
Merck USD 13.42B 431M Sep/2025
Neurocrine Biosciences USD 780.9M 104.7M Sep/2025
Novartis USD 10.82B 695M Sep/2025
Pfizer USD 3.54B 7.61B Sep/2025
Regeneron Pharmaceuticals USD 3.3B 67M Dec/2025
Roche Holding CHF 22.09B 10.04B Dec/2025
Sarepta Therapeutics USD 247.9M 209.96M Sep/2025
TG Therapeutics USD 133.62M 11.41M Sep/2025
Vertex Pharmaceuticals USD 2.66B 104.4M Sep/2025